Meg Alexander
CEO, President & Director
Good morning, everyone, and welcome to Ovid Therapeutics where we are on a journey to pioneer better and gentler medicines for the brain. And one of the ways we’re doing that is with what we think is a portfolio of mechanisms for a very exciting target in the brain, KCC2, which stands for potassium-chloride co-transporter 2. And while we’ve had a lot of progress in our epilepsy pipeline, there has also been tremendous progress in our KCC2 portfolio. So we’re excited to take you through a deep dive today.
I’m Meg Alexander. It’s my privilege to be the President and CEO here at Ovid. And I want to remind you, we are a public company, and we will be making forward-looking statements today.
But why we have been so excited to have you here and host you is to tell you more about our vision for KCC2 direct activation. We’re pioneering an entirely new class of medicines for the brain and a target that we believe is a master switch for excitation and excitatory/inhibitory balance in the brain.
We believe our first molecule — oral molecule, OV4071, is a potential pipeline
